Survival Outcomes Associated With First-Line Procarbazine, CCNU, and Vincristine or Temozolomide in Combination With Radiotherapy in IDH-Mutant 1p/19q-Codeleted Grade 3 Oligodendroglioma

丙卡巴嗪 替莫唑胺 医学 洛莫司汀 内科学 肿瘤科 少突胶质瘤 长春新碱 无进展生存期 达卡巴嗪 化疗 放射治疗 胶质瘤 癌症研究 环磷酰胺 星形细胞瘤
作者
Salah Eddine Oussama Kacimi,Caroline Dehais,L. Feuvret,Olivier Chinot,Alain Carpentier,Charlotte Bronnimann,Élodie Vauléon,Apolline Djelad,Elizabeth Cohen‐Jonathan Moyal,Olivier Langlois,Mario Campone,Mathilde Ducloie,G. Noël,Stefania Cuzzubbo,Luc Taillandier,Carole Ramirez,Nadia Younan,Philippe Meneï,F. Dhermain,C. Desenclos,François Ghiringhelli,Veronique Bourg,Damien Ricard,Thierry Faillot,Romain Appay,Émeline Tabouret,Lucia Nichelli,Bertrand Mathon,Alice Thomas,Suzanne Tran,Franck Bielle,Agustí Alentorn,J. Bryan Iorgulescu,Pierre‐Yves Boëlle,Karim Labreche,Khê Hoang‐Xuan,Marc Sanson,Ahmed Idbaïh,Dominique Figarella‐Branger,François Ducray,Mehdi Touat,C. Desenclos,N. Guillain,Philippe Meneï,Audrey Rousseau,T Cruel,Saioa López,M. Abad,N. Hamdan,Clovis Adam,Fabrice Parker,Romuald Seizeur,Isabelle Quintin‐Roué,Guillaume Chotard,Charlotte Bronnimann,Damien Ricard,Catherine Godfraind,Toufik Khallil,Dominique Cazals‐Hatem,Thierry Faillot,C. Gaultier,M.-C. Tortel,Ioana Carpiuc,Philippe Richard,H. Aubriot-Lorton,François Ghiringhelli,Apolline Djelad,Claude‐Alain Maurage,E.M. Gueye,François Labrousse,François Ducray,David Meyronet,Dominique Figarella‐Branger,Olivier Chinot,Luc Bauchet,Valérie Rigau,G. Gauchotte,Luc Taillandier,Mario Campone,Delphine Loussouarn,Veronique Bourg,F. Vandenbos-Burel,Jean Sébastien Guillamo,Pascal Roger,Claire Bléchet,H. Adle-Biassette,Franck Bielle,Alain Carpentier,Caroline Dehais,Serge Milin,Michel Wager,Philippe Colin,M.D. Diebold,Danchristian Chiforeanu,Élodie Vauléon,Florent Marguet,Olivier Langlois,Fabien Forest,M.J. Motso-Fotso,Marie Andraud,Benoît Lhermitte,G. Noël,Michèle Bernier,Nadia Younan,Cécilia Rousselot-Denis,Ilyess Zemmoura,Christophe Joubert,Elisabeth Cohen-Moyal,Emmanuelle Uro‐Coste,F. Dhermain
出处
期刊:Journal of Clinical Oncology [American Society of Clinical Oncology]
标识
DOI:10.1200/jco.24.00049
摘要

PURPOSE Patients with IDH-mutant 1p/19q-codeleted grade 3 oligodendroglioma (O3 IDHmt/Codel ) benefit from adding alkylating agent chemotherapy to radiotherapy (RT). However, the optimal chemotherapy regimen between procarbazine, 1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU), and vincristine (PCV) and temozolomide (TMZ) remains unclear given the lack of randomized trial data comparing both regimens. METHODS The objective was to assess the overall survival (OS) and progression-free survival (PFS) associated with first-line PCV/RT versus TMZ/RT in patients newly diagnosed with O3 IDHmt/Codel . We included patients with histologically proven O3 IDHmt/Codel (according to WHO criteria) from the French national prospective cohort Prise en charge des OLigodendrogliomes Anaplasiques (POLA). All tumors underwent central pathological review. OS and PFS from surgery were estimated using the Kaplan-Meier method and Cox regression model. RESULTS 305 newly diagnosed patients with O3 IDHmt/Codel treated with RT and chemotherapy between 2008 and 2022 were included, of which 67.9% of patients (n = 207) were treated with PCV/RT and 32.1% with TMZ/RT (n = 98). The median follow-up was 78.4 months (IQR, 44.3-102.7). The median OS was not reached (95% CI, Not reached [NR] to NR) in the PCV/RT group and was 140 months (95% CI, 110 to NR) in the TMZ/RT group (log-rank P = .0033). On univariable analysis, there was a significant difference in favor of PCV/RT in both 5-year (PCV/RT: 89%, 95% CI, 85 to 94; TMZ/RT: 75%, 95% CI, 66 to 84) and 10-year OS (PCV/RT: 72%, 95% CI, 61 to 85; TMZ/RT: 60%, 95% CI, 49 to 73), which was confirmed using the multivariable Cox model adjusted for age, type of surgery, gender, Eastern Cooperative Oncology Group performance status, and CDKN2A homozygous deletion (hazard ratio, 0.53 for PCV/RT, 95% CI, 0.30 to 0.92, P = .025). CONCLUSION In patients with newly diagnosed O3 IDHmt/Codel from the POLA cohort, first-line PCV/RT was associated with better OS outcomes compared with TMZ/RT. Our data suggest that the improved safety profile associated with TMZ comes at the cost of inferior efficacy in this population. Further investigation using prospective randomized studies is warranted.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
等待落雁完成签到,获得积分10
1秒前
梅子完成签到,获得积分20
1秒前
皮蛋发布了新的文献求助10
1秒前
可爱的函函应助超级的班采纳,获得30
1秒前
2秒前
罗踩踩完成签到,获得积分10
2秒前
5秒前
tll完成签到,获得积分10
5秒前
6秒前
SciGPT应助1111111采纳,获得10
6秒前
6秒前
ramu发布了新的文献求助10
8秒前
8秒前
湘华完成签到,获得积分10
8秒前
9秒前
隐形曼青应助浅梦采纳,获得10
10秒前
Sevendesu发布了新的文献求助30
10秒前
10秒前
Akim应助铁柱采纳,获得10
10秒前
调研昵称发布了新的文献求助10
12秒前
登山人发布了新的文献求助10
13秒前
14秒前
15秒前
姚林枝发布了新的文献求助10
16秒前
科目三应助大G采纳,获得10
17秒前
Anderson732发布了新的文献求助10
18秒前
18秒前
18秒前
20秒前
怕黑的山彤完成签到,获得积分10
20秒前
20秒前
wm999发布了新的社区帖子
21秒前
21秒前
浅梦发布了新的文献求助10
21秒前
可爱的函函应助天真山兰采纳,获得10
22秒前
王书娟完成签到,获得积分10
22秒前
科目三应助Youu采纳,获得10
23秒前
23秒前
铁柱发布了新的文献求助10
23秒前
23秒前
高分求助中
Sustainability in Tides Chemistry 2800
Shape Determination of Large Sedimental Rock Fragments 2000
The Young builders of New china : the visit of the delegation of the WFDY to the Chinese People's Republic 1000
Rechtsphilosophie 1000
Bayesian Models of Cognition:Reverse Engineering the Mind 888
Le dégorgement réflexe des Acridiens 800
Defense against predation 800
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3133114
求助须知:如何正确求助?哪些是违规求助? 2784327
关于积分的说明 7765830
捐赠科研通 2439465
什么是DOI,文献DOI怎么找? 1296858
科研通“疑难数据库(出版商)”最低求助积分说明 624757
版权声明 600771